Merck, NanoString Seek to Identify I-O Responders in Rich Companion Dx Deal

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

When Raising Drug Prices Helps Patients
A Busy IPO Calendar: Forma, Repare, Progenity, Genetron
Beyond CAR-T: New Engineered Immune Cell Types Head to the Clinic
Early Cancer Screening is Maturing. What Will It Mean for Drug Developers?